Expertise in
1
conditions

Ramon G. Sanz

Madrid, MD, ES 
Expertise in
1
conditions
Madrid, MD, ES 

Overview

Ramon Sanz practices practicing medicine in Madrid, Spain.

Mr. Sanz is highly rated in 1 condition, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Hodgkin Lymphoma, Multiple Myeloma, and Acute Promyelocytic Leukemia.

He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Madrid, MD, Spain
Other Locations
Salamanca, CL, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

16 Total Publications

Correction: Beyond Binary FISH Results: Targeted NGS Provides Deeper Characterization of MYC and Broader Genomic Alterations in DLBCL.
Correction: Beyond Binary FISH Results: Targeted NGS Provides Deeper Characterization of MYC and Broader Genomic Alterations in DLBCL.
Journal: Molecular diagnosis & therapy
Published: May 22, 2026

Frequently Asked Questions about Ramon G. Sanz

Is Ramon G. Sanz a top-rated expert for Waldenstrom Macroglobulinemia?

MediFind is an objective health platform that identifies experts based on real-world data. Ramon G. Sanz is classified as an Distinguished expert for Waldenstrom Macroglobulinemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ramon G. Sanz participate in research or clinical trials?

Yes. Ramon G. Sanz has published 16 articles and abstracts on conditions like Waldenstrom Macroglobulinemia. You can view a list of Ramon G. Sanz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sanz's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile